2021 APLAR共识声明:系统性红斑狼疮的管理

2021-07-01 亚太风湿病学联盟协会 Lancet Rheumatol

2021年7月,亚太风湿病学联盟(APLAR)制定首个系统性红斑狼疮(SLE)管理共识。共识提出了总体原则和治疗策略,对于狼疮肾炎、神经精神性SLE等并发症也给出治疗建议,共形成34条指导建议。

中文标题:

2021 APLAR共识声明:系统性红斑狼疮的管理

英文标题:

The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus

发布日期:

2021-07-01

简要介绍:

2021年7月,亚太风湿病学联盟(APLAR)制定首个系统性红斑狼疮(SLE)管理共识。共识提出了总体原则和治疗策略,对于狼疮肾炎、神经精神性SLE等并发症也给出治疗建议,共形成34条指导建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021 APLAR共识声明:系统性红斑狼疮的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=bd4ef1c0022108d8, title=2021 APLAR共识声明:系统性红斑狼疮的管理, enTitle=The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus, guiderFrom=Lancet Rheumatol, authorId=0, author=, summary=2021年7月,亚太风湿病学联盟(APLAR)制定首个系统性红斑狼疮(SLE)管理共识。共识提出了总体原则和治疗策略,对于狼疮肾炎、神经精神性SLE等并发症也给出治疗建议,共形成34条指导建议。, cover=https://img.medsci.cn/20211016/1634393145876_5579292.jpg, journalId=0, articlesId=null, associationId=1773, associationName=亚太风湿病学联盟协会, associationIntro=, copyright=0, guiderPublishedTime=Thu Jul 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年7月,亚太风湿病学联盟(APLAR)制定首个系统性红斑狼疮(SLE)管理共识。共识提出了总体原则和治疗策略,对于狼疮肾炎、神经精神性SLE等并发症也给出治疗建议,共形成34条指导建议。</span></p>, tagList=[TagDto(tagId=648, tagName=系统性红斑狼疮)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=648, guiderKeyword=系统性红斑狼疮, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=5, opened=0, paymentType=, paymentAmount=2, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6206, appHits=427, showAppHits=0, pcHits=1595, showPcHits=5778, likes=3, shares=24, comments=12, approvalStatus=1, publishedTime=Sun Oct 17 22:15:30 CST 2021, publishedTimeString=2021-07-01, pcVisible=1, appVisible=1, editorId=1614372, editor=MedSciZeng, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=dajiong, createdTime=Sun Oct 17 21:41:50 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 18:54:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 APLAR共识声明:系统性红斑狼疮的管理.pdf)])
2021 APLAR共识声明:系统性红斑狼疮的管理.pdf
下载请点击:
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2096393, encodeId=3fef20963932d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGCbm9E3lZWe3Bp8FGJicmonNmro16W34v64mZ5P6G6bNiaYCZnsvt93uU10gJ3sjDIiapenJ2Z9Xug/132, createdBy=7f475276184, createdName=186483299em, createdTime=Thu Oct 27 08:13:42 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091096, encodeId=baaf209109622, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f184724815, createdName=824599460, createdTime=Thu Sep 29 21:47:05 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213165, encodeId=1a1b1213165c8, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:55 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212659, encodeId=4457121265909, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:43:12 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203638, encodeId=6e13120363823, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e305452776, createdName=ms2000000991580947, createdTime=Thu Mar 17 22:54:26 CST 2022, time=2022-03-17, status=1, ipAttribution=)]
    2022-10-27 186483299em

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2096393, encodeId=3fef20963932d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGCbm9E3lZWe3Bp8FGJicmonNmro16W34v64mZ5P6G6bNiaYCZnsvt93uU10gJ3sjDIiapenJ2Z9Xug/132, createdBy=7f475276184, createdName=186483299em, createdTime=Thu Oct 27 08:13:42 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091096, encodeId=baaf209109622, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f184724815, createdName=824599460, createdTime=Thu Sep 29 21:47:05 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213165, encodeId=1a1b1213165c8, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:55 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212659, encodeId=4457121265909, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:43:12 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203638, encodeId=6e13120363823, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e305452776, createdName=ms2000000991580947, createdTime=Thu Mar 17 22:54:26 CST 2022, time=2022-03-17, status=1, ipAttribution=)]
    2022-09-29 824599460

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2096393, encodeId=3fef20963932d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGCbm9E3lZWe3Bp8FGJicmonNmro16W34v64mZ5P6G6bNiaYCZnsvt93uU10gJ3sjDIiapenJ2Z9Xug/132, createdBy=7f475276184, createdName=186483299em, createdTime=Thu Oct 27 08:13:42 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091096, encodeId=baaf209109622, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f184724815, createdName=824599460, createdTime=Thu Sep 29 21:47:05 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213165, encodeId=1a1b1213165c8, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:55 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212659, encodeId=4457121265909, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:43:12 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203638, encodeId=6e13120363823, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e305452776, createdName=ms2000000991580947, createdTime=Thu Mar 17 22:54:26 CST 2022, time=2022-03-17, status=1, ipAttribution=)]
    2022-04-21 135434d0m28暂无昵称

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2096393, encodeId=3fef20963932d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGCbm9E3lZWe3Bp8FGJicmonNmro16W34v64mZ5P6G6bNiaYCZnsvt93uU10gJ3sjDIiapenJ2Z9Xug/132, createdBy=7f475276184, createdName=186483299em, createdTime=Thu Oct 27 08:13:42 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091096, encodeId=baaf209109622, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f184724815, createdName=824599460, createdTime=Thu Sep 29 21:47:05 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213165, encodeId=1a1b1213165c8, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:55 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212659, encodeId=4457121265909, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:43:12 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203638, encodeId=6e13120363823, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e305452776, createdName=ms2000000991580947, createdTime=Thu Mar 17 22:54:26 CST 2022, time=2022-03-17, status=1, ipAttribution=)]
    2022-04-19 qqnded

    感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2096393, encodeId=3fef20963932d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIGCbm9E3lZWe3Bp8FGJicmonNmro16W34v64mZ5P6G6bNiaYCZnsvt93uU10gJ3sjDIiapenJ2Z9Xug/132, createdBy=7f475276184, createdName=186483299em, createdTime=Thu Oct 27 08:13:42 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2091096, encodeId=baaf209109622, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f184724815, createdName=824599460, createdTime=Thu Sep 29 21:47:05 CST 2022, time=2022-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213165, encodeId=1a1b1213165c8, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=67df3725267, createdName=135434d0m28暂无昵称, createdTime=Thu Apr 21 15:11:55 CST 2022, time=2022-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212659, encodeId=4457121265909, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc292854358, createdName=qqnded, createdTime=Tue Apr 19 20:43:12 CST 2022, time=2022-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1203638, encodeId=6e13120363823, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4e305452776, createdName=ms2000000991580947, createdTime=Thu Mar 17 22:54:26 CST 2022, time=2022-03-17, status=1, ipAttribution=)]
    2022-03-17 ms2000000991580947

    学习

    0

拓展阅读

2010 系统性红斑狼疮诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-05-01

2010 EULAR 治疗有神经精神症状的系统性红斑狼疮患者的推荐意见

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2010-12-01

2011 中国儿童系统性红斑狼疮诊疗建议

中华医学会儿科学分会免疫学组 · 2011-07-01

2014 靶向治疗系统性红斑狼疮:国际工作组推荐建议

国外风湿免疫科相关专家小组 · 2014-04-16

2014 糖皮质激素在系统性红斑狼疮患者合理应用的专家共识

中国系统性红斑狼疮研究协作组(CSTAR,Chinese SLE Treatment And Research Group) · 2014-06-03